Literature DB >> 23103418

Role of glutamic acid decarboxylase 67 in regulating cortical parvalbumin and GABA membrane transporter 1 expression: implications for schizophrenia.

Allison A Curley1, Stephen M Eggan, Matt S Lazarus, Z Josh Huang, David W Volk, David A Lewis.   

Abstract

Markers of GABA neurotransmission are altered in multiple regions of the neocortex in individuals with schizophrenia. Lower levels of glutamic acid decarboxylase 67 (GAD67) mRNA and protein, which is responsible for most cortical GABA synthesis, are accompanied by lower levels of GABA membrane transporter 1 (GAT1) mRNA. These alterations are thought to be most prominent in the parvalbumin (PV)-containing subclass of interneurons, which also contain lower levels of PV mRNA. Since GAT1 and PV each reduce the availability of GABA at postsynaptic receptors, lower levels of GAT1 and PV mRNAs have been hypothesized to represent compensatory responses to an upstream reduction in cortical GABA synthesis in schizophrenia. However, such cause-and-effect hypotheses cannot be directly tested in a human illness. Consequently, we used two mouse models with reduced GAD67 expression specifically in PV neurons (PV(GAD67+/-)) or in all interneurons (GABA(GAD67+/-)) and quantified GAD67, GAT1 and PV mRNA levels using methods identical to those employed in studies of schizophrenia. Cortical levels of PV or GAT1 mRNAs were not altered in PV(GAD67+/-) mice during postnatal development or in adulthood. Furthermore, cellular analyses confirmed the predicted reduction in GAD67 mRNA, but failed to show a deficit in PV mRNA in these animals. Levels of PV and GAT1 mRNAs were also unaltered in GABA(GAD67+/-) mice. Thus, mouse lines with cortical reductions in GAD67 mRNA that match or exceed those present in schizophrenia, and that differ in the developmental timing and cell type-specificity of the GAD67 deficit, failed to provide proof-of-concept evidence that lower PV and GAT1 expression in schizophrenia are a consequence of lower GAD67 expression. Together, these findings suggest that the correlated decrements in cortical GAD67, PV and GAT1 mRNAs in schizophrenia may be a common consequence of some other upstream factor.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23103418      PMCID: PMC3534919          DOI: 10.1016/j.nbd.2012.10.018

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  53 in total

1.  Synapse density regulates independence at unitary inhibitory synapses.

Authors:  Linda S Overstreet; Gary L Westbrook
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

2.  A prospective study of childhood neurocognitive functioning in schizophrenic patients and their siblings.

Authors:  Tara A Niendam; Carrie E Bearden; Isabelle M Rosso; Laura E Sanchez; Trevor Hadley; Keith H Nuechterlein; Tyrone D Cannon
Journal:  Am J Psychiatry       Date:  2003-11       Impact factor: 18.112

3.  Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics.

Authors:  S Akbarian; J J Kim; S G Potkin; J O Hagman; A Tafazzoli; W E Bunney; E G Jones
Journal:  Arch Gen Psychiatry       Date:  1995-04

4.  Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia.

Authors:  Takanori Hashimoto; David W Volk; Stephen M Eggan; Karoly Mirnics; Joseph N Pierri; Zhuoxin Sun; Allan R Sampson; David A Lewis
Journal:  J Neurosci       Date:  2003-07-16       Impact factor: 6.167

5.  Kinetic differences between the isoforms of glutamate decarboxylase: implications for the regulation of GABA synthesis.

Authors:  Gino Battaglioli; Hongcheng Liu; David L Martin
Journal:  J Neurochem       Date:  2003-08       Impact factor: 5.372

6.  Green fluorescent protein expression and colocalization with calretinin, parvalbumin, and somatostatin in the GAD67-GFP knock-in mouse.

Authors:  Nobuaki Tamamaki; Yuchio Yanagawa; Ryohei Tomioka; Jun-Ichi Miyazaki; Kunihiko Obata; Takeshi Kaneko
Journal:  J Comp Neurol       Date:  2003-12-01       Impact factor: 3.215

7.  The development of parvalbumin-immunoreactivity in the neocortex of the mouse.

Authors:  J A del Río; L de Lecea; I Ferrer; E Soriano
Journal:  Brain Res Dev Brain Res       Date:  1994-09-16

8.  GABA transporter-1 (GAT1)-deficient mice: differential tonic activation of GABAA versus GABAB receptors in the hippocampus.

Authors:  Kimmo Jensen; Chi-Sung Chiu; Irina Sokolova; Henry A Lester; Istvan Mody
Journal:  J Neurophysiol       Date:  2003-06-18       Impact factor: 2.714

9.  GABA transporter mRNA: in vitro expression and quantitation in neonatal rat and postmortem human brain.

Authors:  Y Xia; M S Poosch; C J Whitty; G Kapatos; M J Bannon
Journal:  Neurochem Int       Date:  1993-03       Impact factor: 3.921

10.  Local circuit neurons immunoreactive for calretinin, calbindin D-28k or parvalbumin in monkey prefrontal cortex: distribution and morphology.

Authors:  F Condé; J S Lund; D M Jacobowitz; K G Baimbridge; D A Lewis
Journal:  J Comp Neurol       Date:  1994-03-01       Impact factor: 3.215

View more
  20 in total

1.  Effects of chronic inhibition of GABA synthesis on attention and impulse control.

Authors:  Tracie A Paine; Elizabeth K Cooke; Daniel C Lowes
Journal:  Pharmacol Biochem Behav       Date:  2015-06-01       Impact factor: 3.533

Review 2.  Interneuron epigenomes during the critical period of cortical plasticity: Implications for schizophrenia.

Authors:  Hirofumi Morishita; Marija Kundakovic; Lucy Bicks; Amanda Mitchell; Schahram Akbarian
Journal:  Neurobiol Learn Mem       Date:  2015-04-04       Impact factor: 2.877

3.  Decreasing GABA function within the medial prefrontal cortex or basolateral amygdala decreases sociability.

Authors:  Tracie A Paine; Nathan Swedlow; Lucien Swetschinski
Journal:  Behav Brain Res       Date:  2016-10-11       Impact factor: 3.332

4.  GABAergic control of depression-related brain states.

Authors:  Bernhard Luscher; Thomas Fuchs
Journal:  Adv Pharmacol       Date:  2015-01-14

5.  Transcriptional dysregulation of γ-aminobutyric acid transporter in parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Psychiatry Res       Date:  2014-10-02       Impact factor: 3.222

6.  MiR-200c-3p inhibits cell migration and invasion of clear cell renal cell carcinoma via regulating SLC6A1.

Authors:  Naibijiang Maolakuerban; Baihetiya Azhati; Hamulati Tusong; Asimujiang Abula; Anniwaer Yasheng; Ayiding Xireyazidan
Journal:  Cancer Biol Ther       Date:  2018-02-02       Impact factor: 4.742

7.  Cortical Gene Expression After a Conditional Knockout of 67 kDa Glutamic Acid Decarboxylase in Parvalbumin Neurons.

Authors:  Danko Georgiev; Toru Yoshihara; Rika Kawabata; Takurou Matsubara; Makoto Tsubomoto; Yoshio Minabe; David A Lewis; Takanori Hashimoto
Journal:  Schizophr Bull       Date:  2016-03-15       Impact factor: 9.306

8.  Corresponding decrease in neuronal markers signals progressive parvalbumin neuron loss in MAM schizophrenia model.

Authors:  Kathryn M Gill; Anthony A Grace
Journal:  Int J Neuropsychopharmacol       Date:  2014-04-30       Impact factor: 5.176

Review 9.  Preclinical models of antipsychotic drug action.

Authors:  José L Moreno; Javier González-Maeso
Journal:  Int J Neuropsychopharmacol       Date:  2013-06-10       Impact factor: 5.176

Review 10.  Targeting Prefrontal Cortical Systems for Drug Development: Potential Therapies for Cognitive Disorders.

Authors:  Amy F T Arnsten; Min Wang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016       Impact factor: 13.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.